NEW YORK, July 31 – Lexicon Genetics of The Woodlands, Texas, said Tuesday it had signed a two-year deal to provide Immunex with knockout mammalian models for the pharmaceutical company’s drug development program.

In exchange, Lexicon will receive an up-front technology access fee, annual research funding, and milestone and royalty payments on products developed through the collaboration.

Lexicon did not disclose the specific financial terms of the deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.